Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00318344 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Atuna Racemosa Toxicity
A Phase 1 study of Bacterial Infections, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00318344: Completed Phase 1 study of Bacterial Infections, sponsored by Mayo Clinic.
NCT00318344 is a Phase 1 study of Bacterial Infections that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 140-participant average among 17 other Bacterial Infections trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00318344, a Phase 1 study of Bacterial Infections, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
For thousands of years people in the South Pacific have used Atuna racemosa extract as a topical anti-inflammatory. We, the researchers at the Mayo Clinic, have shown this extract to also have antibacterial properties. While this extract has been used for decades in the South Pacific, a controlled clinical trial to evaluate toxicity has never been performed.
Conditions Studied
Interventions
- DRUG Atuna Racemosa
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00318344
The ClinicalTrials.gov registry entry for NCT00318344 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 17 other Bacterial Infections trials with a reported enrollment target (86% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bacterial Infections appearing as the primary indexed condition, and to 1 intervention - of which Atuna Racemosa is the first listed.
NCT00318344 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00318344 about?
NCT00318344 is a clinical study titled "Evaluation of Atuna Racemosa Toxicity". For thousands of years people in the South Pacific have used Atuna racemosa extract as a topical anti-inflammatory. We, the researchers at the Mayo Clinic, have shown this extract to also have antibacterial properties. While this extract has been used for decades in the South Pacific, a controlled c...
What is the current status of trial NCT00318344?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2006-04. Estimated completion is 2007-11.
What conditions does trial NCT00318344 study?
This clinical trial studies the following conditions: Bacterial Infections.
What interventions are being tested in trial NCT00318344?
The interventions under investigation include: Atuna Racemosa (DRUG).
Who is sponsoring clinical trial NCT00318344?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00318344 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
RECRUITING · Phase 1
-
A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment
RECRUITING · Phase 1
-
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects
COMPLETED · Phase 1
-
Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects
COMPLETED · Phase 1
-
A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity
COMPLETED · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.